Anti-Adalimumab Antibodies in Children With Juvenile Idiopathic Arthritis and/or Chronic Non-Infectious Uveitis (ADA AIG-U)
Anti-Adalimumab Antibodies in a Prospective Cohort of Patients With Juvenile Idiopathic Arthritis and/or Chronic Non-Infectious Uveitis: Incidence, Predictive Factors, and Clinical Correlations
This prospective, single-center observational cohort study aims to investigate the development of anti-Adalimumab antibodies in pediatric patients with juvenile idiopathic arthritis (JIA) and/or chronic non-infectious uveitis initiating Adalimumab treatment.
The study will assess the frequency and timing of antibody development, identify potential predictive factors, including concomitant methotrexate treatment, and explore associations between immunogenicity, serum Adalimumab concentrations, disease activity, and clinical outcomes.
A total of 60 patients will be enrolled and followed for 24 months. Clinical data and additional blood samples will be collected at baseline and at 3, 6, 12, 18, and 24 months during routine clinical visits.
Anti-Adalimumab antibodies and serum drug concentrations will be measured using surface plasmon resonance (SPR) technology. Treatment decisions will remain entirely based on routine clinical practice.
研究概览
详细说明
Adalimumab is widely used in the treatment of juvenile idiopathic arthritis (JIA) and chronic non-infectious uveitis. Despite its established efficacy, some patients experience inadequate clinical response, secondary loss of efficacy, or disease flares during treatment. The development of anti-Adalimumab antibodies (AAA) may contribute to reduced serum drug concentrations and impaired therapeutic response. However, evidence regarding the incidence, timing, and clinical significance of AAA in paediatric patients remains limited and heterogeneous.
This prospective, single-centre, observational cohort study aims to investigate the development and kinetics of AAA in paediatric patients with JIA and/or chronic non-infectious uveitis initiating Adalimumab treatment. The study will also explore potential predictive factors for AAA development, including concomitant methotrexate therapy, and evaluate associations between immunogenicity, serum Adalimumab concentrations, disease activity, and clinical outcomes.
A total of 60 Adalimumab-naïve patients will be consecutively enrolled at AOU Meyer IRCCS, Florence, Italy. All participants will receive Adalimumab according to routine clinical practice, independently of study participation. No investigational treatment or study-related therapeutic intervention is planned.
Each participant will be followed for 24 months, with assessments at baseline and at 3, 6, 12, 18, and 24 months. Clinical and laboratory data will be collected during routine follow-up visits, including demographic characteristics, disease subtype and duration, concomitant treatments, disease activity measures, inflammatory markers, disease flares, and treatment modifications.
At each scheduled assessment, an additional 5 mL peripheral blood sample will be collected during routine blood sampling. Serum samples will be analysed at the PeptLab laboratory of the University of Florence using surface plasmon resonance (SPR) technology to determine AAA positivity and levels, as well as serum Adalimumab concentrations. AAA positivity will be defined according to a predefined threshold of 15 Response Units (RU).
The primary outcomes are the proportion of patients developing AAA during follow-up and the time from Adalimumab initiation to the first detection of AAA. Secondary outcomes include the identification of clinical and treatment-related factors associated with AAA development, changes in disease activity and functional assessment scores (JADAS-10 and CHAQ), inflammatory markers, occurrence and number of disease flares, and persistence of AAA positivity.
Statistical analyses will include descriptive and exploratory multivariable methods, longitudinal models for repeated measurements, and time-to-event analyses accounting for interval censoring when appropriate. Particular attention will be given to the potential association between concomitant methotrexate treatment and AAA development.
The overall study duration is expected to be 72 months, including 36 months of recruitment, individual follow-up, and final data analysis and reporting.
The study aims to improve understanding of Adalimumab immunogenicity in paediatric JIA and chronic non-infectious uveitis and to explore the potential clinical value of immunopharmacological monitoring in identifying patients at risk of secondary treatment failure or disease relapse.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:LUCIA PAOLINI
- 电话号码:390555662499
- 邮箱:lucia.paolini@meyer.it
学习地点
-
-
-
Florence、意大利
- 招聘中
- Aou Meyer IRCSS
-
接触:
- LUCIA PAOLINI
- 电话号码:+390555662545
- 邮箱:lucia.paolini@meyer.it
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Pediatric patients with juvenile idiopathic arthritis (JIA) and/or chronic non-infectious uveitis followed at the Pediatric Rheumatology Unit of AOU Meyer IRCCS, Florence, Italy, for whom initiation of Adalimumab treatment is clinically indicated.
Eligible patients must be Adalimumab-naïve and will be consecutively enrolled during routine outpatient or day-hospital visits. Treatment decisions will be made independently of study participation, according to standard clinical practice.
描述
Inclusion Criteria:
Age at diagnosis between 2 and 16 years.
Diagnosis of juvenile idiopathic arthritis (JIA) according to the International League of Associations for Rheumatology (ILAR) criteria, established on or after January 1, 2015, and/or diagnosis of chronic non-infectious uveitis according to the Standardization of Uveitis Nomenclature (SUN) Working Group criteria, established on or after January 1, 2015.
Clinical indication to initiate Adalimumab treatment in patients with no previous exposure to Adalimumab (Adalimumab-naïve), as determined by the treating physician.
Written informed consent from parents or legal guardians and assent from minors aged 7 years or older, where applicable.
Exclusion Criteria:
Age 18 years or older at enrollment.
Diagnoses other than juvenile idiopathic arthritis or chronic non-infectious uveitis.
Contraindications to Adalimumab, including tuberculosis exposure, history of multiple sclerosis or other demyelinating central nervous system disorders, or history of malignancy.
Previous exposure to Adalimumab before study enrollment.
Body weight below 12 kg.
Age below 24 months at enrollment.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Adalimumab-treated patients with JIA and/or chronic non-infectious uveitis
Pediatric patients diagnosed with juvenile idiopathic arthritis (JIA) and/or chronic non-infectious uveitis who are initiating Adalimumab treatment according to routine clinical practice and have not previously received Adalimumab. Patients will be prospectively followed for 24 months, with clinical assessments and blood sample collection at baseline and at 3, 6, 12, 18, and 24 months to evaluate the development of anti-Adalimumab antibodies, serum drug concentrations, and clinical outcomes. |
Anti-Adalimumab Antibody and Serum Drug Level Assessment by SPR |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of Patients Developing Anti-Adalimumab Antibodies
大体时间:Baseline and Months 3, 6, 12, 18, and 24
|
Proportion of patients with detectable anti-Adalimumab antibodies (AAA) during the 24-month follow-up, assessed using surface plasmon resonance (SPR). Antibody positivity will be defined using a predefined cut-off of 15 Response Units (RU). |
Baseline and Months 3, 6, 12, 18, and 24
|
|
Time to Development of Anti-Adalimumab Antibodies
大体时间:From baseline to Month 24.
|
Time from initiation of Adalimumab treatment to the first detection of anti-Adalimumab antibodies, assessed at scheduled follow-up visits. The analysis will account for interval censoring between the last negative and first positive antibody determinations. |
From baseline to Month 24.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Factors Associated With Anti-Adalimumab Antibody Development
大体时间:Baseline to Month 24
|
Assessment of the association between anti-Adalimumab antibody (AAA) development and demographic, clinical, and laboratory factors, including sex, age, JIA subtype according to ILAR classification, disease duration, baseline inflammatory markers, and serum Adalimumab concentrations. |
Baseline to Month 24
|
|
Association Between Concomitant Methotrexate Treatment and AAA Development
大体时间:Baseline to Month 24
|
Assessment of the proportion of patients developing anti-Adalimumab antibodies according to concomitant methotrexate treatment (yes/no), including the time to antibody development where appropriate. |
Baseline to Month 24
|
|
Change in Juvenile Arthritis Disease Activity Score (JADAS-10)
大体时间:Baseline and Months 3, 6, 12, 18, and 24
|
Assessment of changes in disease activity using the Juvenile Arthritis Disease Activity Score (JADAS-10) during follow-up and their association with anti-Adalimumab antibody development. |
Baseline and Months 3, 6, 12, 18, and 24
|
|
Change in Childhood Health Assessment Questionnaire (CHAQ) Score
大体时间:Baseline and Months 3, 6, 12, 18, and 24
|
Assessment of changes in functional disability using the Childhood Health Assessment Questionnaire (CHAQ) during follow-up and their association with anti-Adalimumab antibody development. |
Baseline and Months 3, 6, 12, 18, and 24
|
|
Change in Inflammatory Markers (ESR and CRP)
大体时间:Baseline and Months 3, 6, 12, 18, and 24
|
Assessment of changes in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels during follow-up and their association with anti-Adalimumab antibody development. |
Baseline and Months 3, 6, 12, 18, and 24
|
|
Proportion of Patients Experiencing at Least One Disease Flare
大体时间:Baseline to Month 24
|
Proportion of patients experiencing at least one articular or ocular disease flare during the 24-month follow-up, according to the definitions established in the study protocol. |
Baseline to Month 24
|
|
Number of Disease Flares per Patient
大体时间:Baseline to Month 24
|
Total number of articular and/or ocular disease flares recorded for each patient during the 24-month follow-up period. |
Baseline to Month 24
|
|
Persistence of Anti-Adalimumab Antibody Positivity
大体时间:Baseline to Month 24
|
Proportion of anti-Adalimumab antibody-positive patients showing persistent antibody positivity, defined as two positive determinations performed at least six months apart. |
Baseline to Month 24
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.